Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 … Read more
Jiangsu Recbio Technology Co., Ltd. (G93) - Net Assets
Latest net assets as of June 2025: €177.63 Million EUR
Based on the latest financial reports, Jiangsu Recbio Technology Co., Ltd. (G93) has net assets worth €177.63 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.54 Billion) and total liabilities (€1.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €177.63 Million |
| % of Total Assets | 11.51% |
| Annual Growth Rate | -31.86% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.63 |
Jiangsu Recbio Technology Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Jiangsu Recbio Technology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangsu Recbio Technology Co., Ltd. (2021–2024)
The table below shows the annual net assets of Jiangsu Recbio Technology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €529.32 Million | -50.57% |
| 2023-12-31 | €1.07 Billion | -35.22% |
| 2022-12-31 | €1.65 Billion | -1.21% |
| 2021-12-31 | €1.67 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Recbio Technology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 289667700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.43 Billion | 647.24% |
| Total Equity | €529.32 Million | 100.00% |
Jiangsu Recbio Technology Co., Ltd. Competitors by Market Cap
The table below lists competitors of Jiangsu Recbio Technology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KPX Chemical
KO:025000
|
$55.13 Million |
|
Me2on Co. Ltd
KQ:201490
|
$55.14 Million |
|
Surrozen Inc
NASDAQ:SRZN
|
$55.14 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
$55.15 Million |
|
ZENTEK LTD.
F:ZAY0
|
$55.12 Million |
|
T'way Air Co Ltd
KO:091810
|
$55.09 Million |
|
Hot Chili Limited
OTCQX:HHLKF
|
$55.09 Million |
|
Gogolook Co Ltd
TW:6902
|
$55.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Recbio Technology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,071,436,000 to 529,324,000, a change of -542,112,000 (-50.6%).
- Net loss of 562,389,000 reduced equity.
- Other factors increased equity by 20,277,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-562.39 Million | -106.25% |
| Other Changes | €20.28 Million | +3.83% |
| Total Change | €- | -50.60% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Recbio Technology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.11x to 0.39x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.73 | €0.42 | x |
| 2022-12-31 | €3.44 | €0.42 | x |
| 2023-12-31 | €2.22 | €0.42 | x |
| 2024-12-31 | €1.10 | €0.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Recbio Technology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.67x
- Recent ROE (-106.25%) is below the historical average (-60.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -39.30% | 0.00% | 0.00x | 1.15x | €-824.89 Million |
| 2022 | -43.49% | 0.00% | 0.00x | 1.39x | €-888.89 Million |
| 2023 | -53.38% | 0.00% | 0.00x | 2.04x | €-679.10 Million |
| 2024 | -106.25% | 0.00% | 0.00x | 3.67x | €-615.32 Million |
Industry Comparison
This section compares Jiangsu Recbio Technology Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Recbio Technology Co., Ltd. (G93) | €177.63 Million | -39.30% | 7.68x | $55.13 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |